These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 26324949)

  • 21. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
    Tanaka Y; Hirata S; Kubo S; Fukuyo S; Hanami K; Sawamukai N; Nakano K; Nakayamada S; Yamaoka K; Sawamura F; Saito K
    Ann Rheum Dis; 2015 Feb; 74(2):389-95. PubMed ID: 24288014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.
    Bartelds GM; Krieckaert CL; Nurmohamed MT; van Schouwenburg PA; Lems WF; Twisk JW; Dijkmans BA; Aarden L; Wolbink GJ
    JAMA; 2011 Apr; 305(14):1460-8. PubMed ID: 21486979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
    Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical relevance of monitoring serum levels of adalimumab in patients with rheumatoid arthritis in daily practice.
    Rosas J; Llinares-Tello F; de la Torre I; Santos-Ramírez C; Senabre-Gallego JM; Valor L; Barber-Vallés X; Hernández-Flórez D; Santos-Soler G; Salas-Heredia E; Carreño L;
    Clin Exp Rheumatol; 2014; 32(6):942-8. PubMed ID: 25327159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
    Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
    J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
    Roblin X; Rinaudo M; Del Tedesco E; Phelip JM; Genin C; Peyrin-Biroulet L; Paul S
    Am J Gastroenterol; 2014 Aug; 109(8):1250-6. PubMed ID: 24913041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
    Weinblatt ME; Baranauskaite A; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Baek I; Ghil J
    Arthritis Rheumatol; 2018 Jun; 70(6):832-840. PubMed ID: 29439289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The efficiency and safety of adalimumab treatment in patients with active rheumatoid arthritis unresponsive to standard therapy: Russian national study results].
    Karateev DE; Nasonov EL; Luchikhina EL; Mazurov VI; Salikhov IG; Shmidt EI; Shostak NA
    Ter Arkh; 2012; 84(8):22-8. PubMed ID: 22994084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis.
    Paul S; Marotte H; Kavanaugh A; Goupille P; Kvien TK; de Longueville M; Mulleman D; Sandborn WJ; Vande Casteele N
    Clin Transl Sci; 2020 Jul; 13(4):743-751. PubMed ID: 32100960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification.
    Paul S; Williet N; Nancey S; Veyrard P; Boschetti G; Phelip JM; Flourie B; Roblin X
    Dig Dis Sci; 2021 Aug; 66(8):2744-2749. PubMed ID: 32936345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Adalimumab on Work Productivity and Activity Impairment in Japanese Patients with Rheumatoid Arthritis: Large-Scale, Prospective, Single-Cohort ANOUVEAU Study.
    Takeuchi T; Nakajima R; Komatsu S; Yamazaki K; Nakamura T; Agata N; Igarashi A; Tango T; Tanaka Y
    Adv Ther; 2017 Mar; 34(3):686-702. PubMed ID: 28144917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
    Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
    Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.
    Gonczi L; Kurti Z; Rutka M; Vegh Z; Farkas K; Lovasz BD; Golovics PA; Gecse KB; Szalay B; Molnar T; Lakatos PL
    BMC Gastroenterol; 2017 Aug; 17(1):97. PubMed ID: 28789636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of adalimumab and etanercept trough levels and drug antibodies in long-term psoriasis treatment: a single-centre cohort study.
    Manriquez J; Alsina-Gibert M
    Clin Exp Dermatol; 2017 Jan; 42(1):14-20. PubMed ID: 27943384
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation.
    van Schouwenburg PA; Krieckaert CL; Rispens T; Aarden L; Wolbink GJ; Wouters D
    Ann Rheum Dis; 2013 Oct; 72(10):1680-6. PubMed ID: 23300118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.
    Taylor PC; Genovese MC; Greenwood M; Ho M; Nasonov E; Oemar B; Stoilov R; Vencovsky J; Weinblatt M
    Ann Rheum Dis; 2015 Dec; 74(12):2123-9. PubMed ID: 25074688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study.
    Cantini F; Niccoli L; Cassarà E; Kaloudi O; Nannini C
    Biologics; 2012; 6():201-6. PubMed ID: 22904612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.
    Aletaha D; Funovits J; Keystone EC; Smolen JS
    Arthritis Rheum; 2007 Oct; 56(10):3226-35. PubMed ID: 17907167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.